Integrated Analysis of Distant Metastasis-Associated Genes and Potential Drugs in Colon Adenocarcinoma

Miaowei Wu, Weiyang Lou, Meng Lou, Peifen Fu and Xiao-Fang Yu

Background: Most colon adenocarcinoma (COAD) patients die of distant metastasis, though there are some therapies for metastatic COAD. However, the genes exclusively expressed in metastatic COAD remain unclear. This study aims to identify prognosis-related genes associated with distant metastasis and develop therapeutic strategies for COAD patients.

Methods: Transcriptomic data from The Cancer Genome Atlas (TCGA; n = 514) cohort were analyzed as a discovery dataset. Next, the data from the GEPIA database and PROGgeneV2 database were used to validate our analysis. Key genes were identified based on the differential miRNA and mRNA expression with respect to M stage. The potential drugs targeting candidate differentially expressed genes (DEGs) were also investigated.

Results: A total of 127 significantly DEGs in patients with distant metastasis compared with patients without distant metastasis were identified. Then, four prognosis-related genes (LEP, DLX2, CLSTN2, and REG3A) were selected based on clustering analysis and survival analysis. Finally, three compounds targeting the candidate DEGs, including ajmaline, TTNPB, and dydrogesterone, were predicted to be potential drugs for COAD.

Conclusions: This study revealed that distant metastasis in COAD is associated with a specific group of genes, and three existing drugs may suppress the distant metastasis of COAD.

Keywords: colon adenocarcinoma, metastasis, survival, drug, bioinformatics analysis

INTRODUCTION

Distant metastasis accounts for a major proportion of cancer-related mortality, including colon carcinoma, which makes up to 10% of the global burden of cancer (1). Colon adenocarcinoma (COAD) is the most common histological subtype of colon carcinoma and has a poor prognosis (2). To date, metastatic colon carcinoma is incurable in most cases, though there are some treatment options for metastatic disease, such as fluoropyrimidine-based chemotherapy, anti-VEGF agents, anti-EGFR drugs, and immunotherapy (3). Previous studies of COAD focused on the prognostic models and regulators of metastasis (4, 5). However, the genes exclusively expressed in metastatic COAD have yet to provide novel biomarkers and drug targets for use in the clinic.
Differences in the gene expression spectrum between primary and metastatic COAD, which are important for finding cancer biomarkers, have not been thoroughly evaluated. Recent advances in colon carcinoma highlight the urgent need for molecular markers and therapeutic targets in the management of metastatic cancer (6, 7). Here, we screened the differentially expressed gene (DEG) profiles of primary tumor from COAD patients with distant metastasis (M1) compared with those of patients without distant metastasis (M0) in The Cancer Genome Atlas (TCGA) database. Finally, we identified and validated four prognosis-related genes as well as three potential drugs for COAD based on bioinformatics analysis.

MATERIALS AND METHODS

The TCGA Cohort

The RNA-Seq gene expression profiles (Counts format) of COAD patients were downloaded from the TCGA database (https://portal.gdc.cancer.gov/) in March 2020. Clinical data, such as gender, age, tumor grade, clinical stage, and survival time, were also downloaded from the TCGA portal. Next, according to the American Joint Committee on Cancer (AJCC) staging system, we enrolled COAD samples that pathologic M Stage were M0 (n = 334) and M1 (n = 62), while COAD samples that pathologic M Stage were MX or missing were excluded. Then, R software was used for data extraction and sorting to obtain the gene expression matrices and clinical data.

Screening the Differentially Expressed miRNAs (DEmiRNAs) and DEGs

The miRNA differential expression analysis was conducted using the “edgeR” package in Bioconductor (https://bioconductor.org/). The related codes were run in R, and the DEmiRNAs and DEGs in the primary tumors of patients with distant metastasis (M1) compared with those of patients without distant metastasis (M0) were analyzed through the “edgeR” package. P < 0.05 and |fold change (FC)| > 1 were set as the thresholds for identifying DE-miRNAs and DEGs. The package “pheatmap” was used for clustering and heat map construction.

Predicting the Target Genes of DEmiRNAs

The target genes of the DEmiRNAs were identified using mirDIP v4.1 (http://ophid.utoronto.ca/mirDIP/index.jsp), an integrative database containing nearly 152 million human microRNA-target predictions, which were collected across 30 different resources (8). Then, the common DEGs identified by the above two methods were presented as Venn diagrams and identified as candidate DEGs.

Protein-Protein Interaction (PPI) Network and miRNA-Gene Network Construction

The PPI network and miRNA-gene network were successively constructed. The candidate DEGs were first mapped to the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (http://string-db.org) to assess the functional associations among the target genes (9). Only interactions with a combined score of > 0.4 were considered significant. Next, to obtain the hub genes, the degree of connectivity in the PPI network was analyzed by Cytoscape software (version 3.6.0) (10), after which the top 30 hub genes were screened and their PPI subnetwork was established.

To establish the regulatory network of DEmiRNAs and hub genes, first, the upregulated DEmiRNAs and the downregulated hub genes were mapped based on the mirDIP database. In the same way, the downregulated DEmiRNAs and the upregulated hub genes were mapped. Based on this, two miRNA-hub gene regulatory networks were constructed using Cytoscape software (version 3.6.0).

Screening Prognosis-Related Genes

The Gene Expression Profiling Interactive Analysis (GEPIA) database (http://gepia2.cancer-pku.cn/), an interactive web server for analyzing the RNA-Seq expression data from the TCGA and GTEx projects, was used to analyze the prognostic significance of the screened candidate DEGs in COAD (11). In addition, the PROGgeneV2 database (http://www.compbio.iupui.edu/proggene), a web application for analyzing the prognostic significances of mRNA biomarkers in 18 cancers that combines public repositories such as Gene Expression Omnibus (GEO), European Bioinformatics Institute (EBI) ArrayExpress, and TCGA (12), was used to study the prognostic relevance of the key genes associated with distant metastasis. Furthermore, the package “survival” was used to plot the Kaplan-Meier survival curves of the TCGA-COAD cohort. In survival analysis, patients were divided into low-expression and high-expression groups based on the median value of the corresponding genes expression.

DIANA-miRPath (v3.0; http://www.microrna.gr/miRPathv3) was used to identify the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways associated with the DEmiRNAs (13). Metascape (https://metascape.org/), an integrated portal providing a comprehensive gene list annotation and analysis resource by combining functional enrichment, interactome analysis, gene annotation, and membership search based on over 40 independent knowledge bases (14), was used to analyze the enriched terms (Gene Ontology (GO)/KEGG terms, canonical pathways, hallmark gene sets, etc.) of the candidate DEGs. Additionally, the AmiGO database (v2.0; http://amigo.geneontology.org/amigo/) was used to analyze the GO terms of the prognosis-related genes (15).

Next, the Comparative Toxicogenomics Database (CTD) (http://ctdbase.org/) was used to find integrated chemical-gene, chemical-disease, and gene-disease interactions to generate expanded networks and predict novel associations (16). Here, relationships between prognosis-related genes and diseases were investigated.

Survival Curve and Risk Score

After prognosis-related genes were detected, we used stepwise multivariate Cox regression analysis in the “survival” package to build a gene signature panel. Patients were divided into high- and low-risk groups using the median risk score, and Kaplan-Meier curves were used to explore overall survival (OS) of the two groups using the “survminer” package. The survival
receiver operating characteristic curve (ROC) was drawn and the area under the curve (AUC) was calculated for evaluating prognostic value.

**Prediction of Novel Drugs for COAD**

The Connectivity Map (CMap) ([https://portals.broadinstitute.org/cmap/](https://portals.broadinstitute.org/cmap/)) (17) is a platform for finding connections among small molecules that share the same mechanism of action and associations with chemicals and physiological processes, diseases, and drugs. In the present study, the candidate DEGs were divided into two groups: up- and downregulated genes. The upregulated and downregulated genes were subsequently uploaded to query CMap, and searches were made for small-molecule compounds. Scores ranged from −1 to 1, representing the relationship between the drugs and input genes, and drugs with a score of ≤−0.75 (p < 0.05, percent non-null > 50) were considered candidate drugs.

Then, the above results were validated using the CTD (http://ctdbase.org/), which contains associations among chemicals, gene products, and diseases (16).

**ONCOMINE Analysis**

ONCOMINE gene expression array datasets ([https://www.oncomine.org/](https://www.oncomine.org/)), an online cancer microarray database containing 715 gene expression data sets and data from 36 86,733 cancerous and normal tissues, was used to analyze the transcription levels of the four identified genes in colorectal cancer. The mRNA expressions of LEP, DLX2, CLSTN2, and REG3A in colorectal cancer specimens were compared with that in normal controls, using a Student's t-test to generate a p-value.

**Tumor Immune Estimation Resource (TIMER) Database Analysis**

The Tumor Immune Estimation Resource (TIMER) (18) is an integrative web server for evaluating tumor-infiltrating immune cells across diverse cancer types ([https://cistrome.shinyapps.io/timer/](https://cistrome.shinyapps.io/timer/)). The TIMER includes more than 10,000 samples across multiple cancer types of the TCGA. It applies a partial deconvolution linear least square regression method to calculate the abundance of immune infiltrates. We investigated the correlations between the identified genes expression and immune infiltrates in tumors, including CD8+ T cells, CD4+ T cells, dendritic cells, neutrophils, B cells, and macrophages. The Correlation module was used to draw the expression scatterplots comparing a pair of user-defined genes in COAD (n = 457), together with the Spearman's correlation and estimated statistical significance. The identified genes were represented on the y-axis with gene symbols, whereas the metastasis-related immune markers were placed on the x-axis. The gene expression levels were determined with log2 RSEM. Options used for partial correlation conditioned on tumor purity were also used.

**RESULTS**

To explore the prognostic markers specifically expressed in metastatic COAD and novel therapeutic strategies, the present study was designed and analyzed according to the flow chart shown in Figure 1. The patients’ clinicopathological characteristics of are listed in Table 1. The specific analysis processes are shown in detail in the following figures and tables.

**DEmiRNAs and Their Target Genes**

To screen DEmiRNAs from the miRNA-Seq dataset of the TCGA cohort, we conducted a differential expression analysis using the "edgeR" software package. In this cohort, 61/391 (15.6%) of the DEmiRNAs were from patients with stage M1, and 317/379 (83.6%) were from patients with stage M0. Then, 14 DEmiRNAs with a critical point of |log2FC| > 1| and p < 0.05, were obtained, including 8 upregulated DEmiRNAs and 6 downregulated DEmiRNAs (Table 2). The heat map and volcano plot are shown in Figure 2. Additionally, 8,918 potential target genes for the 8 upregulated miRNAs and 5,354 potential target genes for the 6 downregulated miRNAs were determined by using the mirDIP database.

**Identification of DEGs**

To acquire DEGs from the mRNA-Seq dataset of the TCGA cohort, we conducted a differential expression analysis using the “edgeR” software package. In this cohort, 61/391 (15.6%) of the DEGs were from patients with stage M1, and 330/391 (84.4%) were from patients with stage M0. Then, 1,071 DEGs with a critical point of |log2FC| > 1| and p < 0.05 were identified. Among these DEGs, 709 DEGs were upregulated and 362 DEGs were downregulated in the metastatic group (Supplementary Table 1). The heat map and volcano plot are displayed in Figure 3. The overlap between the targets of the DEmiRNAs and the DEGs was determined, revealing 127 shared genes (Figure 4A). We focused our analysis on these 127 genes, which were defined as candidate DEGs (Supplementary Table 2).

**Functional Annotation and Pathway Enrichment Analysis**

To analyze the enriched pathways of the DEmiRNAs, we carried out KEGG pathway enrichment analysis using the DIANA bioinformatic tool. The 14 DEmiRNAs were significantly enriched in cancer and metastasis-related pathways, such as the cell cycle, adherens junction, and p53 signaling pathway (Figure 4B).

Moreover, pathway and process enrichment analyses were conducted based on the 127 candidate DEGs. The top 12 involved clusters were “NABA matrisome associated,” “forebrain neuron differentiation,” “cell-cell adhesion via plasma-membrane adhesion molecules,” “skin development,” “blood circulation,” “peptide cross-linking,” “neuronal system,” “forelimb morphogenesis,” “acute-phase response,” “hormone metabolic process,” “glucuronidation,” and “bile secretion” (Figure 4C). Specifically, among these candidate DEGs, 10 genes participated in cell-cell adhesion via the plasma membrane adhesion molecule biological process, including DSG1, CDH9, SLITRK1, CLDN19, PCDHA9, PCDH11Y, PCDHGB7, CLSTN2, REG3A, and CLDN18, which were considered potential metastasis-related DEGs.
FIGURE 1 | Schematic diagram of the study design. The TCGA-COAD cohort was used to identify the differentially expressed miRNAs (DEmiRNAs) and genes (DEGs) between primary COAD patients and metastatic COAD patients. In brief, 14 miRNAs and 1,071 genes were identified as DEmiRNAs and DEGs, respectively. Subsequently, 14,272 genes were identified as targets of the 14 DEmiRNAs. The 14,272 targets and 1,071 DEGs were overlapped. Next, the common gene set consisting of 127 genes were analyzed. As a result, four candidate genes associated with prognosis were obtained by combining the top 30 hub genes with genes involved in metastasis-related processes. Additionally, three potential small-molecule drugs for COAD were predicted using the CMap database and further validated in CTD.
TABLE 1 | Clinicopathological characteristics of COAD patients.

| Variables                        | Non-dist (n = 334) | Dist (n = 62) |
|----------------------------------|-------------------|--------------|
| Average Patient Age, years (range) | 67.83 (31-90)     | 64.15 (35-85) |
| Sex                              |                   |              |
| Male                             | 176               | 32           |
| Female                           | 158               | 30           |
| Histological type                |                   |              |
| Adenocarcinaoma, NOS             | 283               | 54           |
| Mucinous adenocarcinaoma         | 46                | 7            |
| Others                           | 5                 | 1            |
| Pathologic tumor stage (AJCC)    |                   |              |
| I                                | 67                | 0            |
| II                               | 161               | 0            |
| III                              | 103               | 0            |
| IV                               | 0                 | 62           |
| Pathologic T stage (AJCC)        |                   |              |
| T1                               | 8                 | 0            |
| T2                               | 67                | 0            |
| T3                               | 236               | 38           |
| T4                               | 23                | 24           |
| Pathologic N stage (AJCC)        |                   |              |
| N0                               | 231               | 8            |
| N1                               | 64                | 25           |
| N2                               | 39                | 29           |
| Pathologic M stage (AJCC)        |                   |              |
| M0                               | 334               | 0            |
| M1                               | 0                 | 62           |

COAD, colon adenocarcinaoma; NOS, not otherwise specified; AJCC, American Joint Committee on Cancer.

TABLE 2 | Identification of differentially expressed miRNAs (DEmiRNAs) in TCGA-COAD patients with or without distant metastasis.

| DEmiRNAs  | Log2FC  | p-value   | FDR    |
|-----------|---------|-----------|--------|
| hsa-miR-205-5p | 2.983302 | 9.58E-10  | 8.29E-08 |
| hsa-miR-137  | 2.972022 | 4.02E-28  | 2.09E-25 |
| hsa-miR-431-3p | 2.068659 | 7.05E-12  | 7.32E-10 |
| hsa-miR-187-5p | 2.032728 | 8.29E-15  | 1.43E-12 |
| hsa-miR-3606-5p | 1.815279 | 7.79E-08  | 4.49E-06 |
| hsa-miR-208a-5p | 1.534453 | 5.60E-12  | 7.27E-10 |
| hsa-miR-944  | 1.469469 | 1.59E-21  | 4.12E-19 |
| hsa-miR-301a-5p | 1.030107 | 1.30E-08  | 9.63E-07 |
| hsa-miR-374b-3p | −1.11184 | 0.000342  | 0.080688 |
| hsa-miR-1912 | −1.19534 | 3.76E-06  | 0.01148 |
| hsa-miR-589-5p | −1.64981  | 2.61E-06  | 0.000104 |
| hsa-miR-3145-5p | −2.01733  | 0.000159  | 0.004113 |
| hsa-miR-588  | −2.35543 | 4.73E-08  | 3.07E-06 |
| hsa-miR-590-5p | −2.36745  | 1.27E-06  | 5.89E-05 |

DEmiRNAs, differentially expressed microRNAs; TCGA-COAD, The Cancer Genome Atlas Cancer Genome Atlas - Colon adenocarcinaoma.

Construction of the PPI Network and Regulatory miRNA-Hub Gene Networks

The PPI network of COAD metastasis-associated genes was constructed using the STRING database. Data from this database suggested that most of these genes could interact with each other. The top 30 hub genes were screened out according to the node degree (Figure 4D). For the upregulated genes, the hub genes were ATP2B3, MMD2, FOXG1, LEP, DSG1, GABRG2, MYO3A, KL, CXCL5, DLX2, SCN1A, LHX9, AQP4, DLX1, ATP2B2, HRH3, ASTN1, SLITRK1, and CHRNA4. For the downregulated genes, the hub genes were CXCL11, CXCL9, UGT2B4, SBSN, CRP, IDO1, TCHH, SPRR2E, SPRR2B, IVL, and ALDH1A2.

Next, the miRNA-hub gene networks were constructed using Cytoscape (Figure 5). Among the top 30 hub genes, we found that nine hub genes (IVL, UGT3B4, IDO1, CRP, TCHH, ALDH1A2, SPRR2B, SPRR2E, and SBSN) could be potentially modulated by upregulated miR-431-3p, while ALDH1A2 could also be potentially modulated by upregulated miR-137. Moreover, 11 hub genes could be regulated by downregulated miR-590-5p, including MYO3A, CXCL5, LHX9, SCN1A, DSG1, DLX2, DLX1, AQP4, FOXG1, GABRG2, and KL. Additionally, SCN1A could be potentially modulated by the downregulation of miR-3145-5p and miR-374b-3p. Moreover, downregulated miR-588 could potentially modulate four hub genes, including AQP4, FOXG1, LEP, and MMD2.

Determination of Key Genes Correlated With Prognosis in COAD

To screen the prognostic genes, Kaplan-Meier analysis was performed based on the expression levels of the hub genes in the TCGA-COAD cohort. Among the top 30 hub genes, we found that two genes (LEP and DLX2) were significantly associated with overall survival (OS), and these genes were considered risky genes, with hazard ratio (HR) > 1 (p < 0.05; Figures 6A,B). Furthermore, for patients with stage M0 disease, higher levels of LEP and DLX2 were markedly associated with worse OS (p < 0.05; Figures 6C,D). However, for patients with stage M1, the expression of LEP had no significant effect on OS (Figure 7A), but higher DLX2 expression had significantly correlated with worse OS (p < 0.05; Figure 7B). In addition, COAD patients with higher LEP expression had worse OS and disease-free survival (DFS) (p < 0.05; Figures 7A,B). In addition, COAD patients with higher DLX2 expression had worse OS (p < 0.05; Figure 7C), but DLX2 expression had no significant effect on DFS (Figure 7D).

Subsequently, we further investigated the prognostic roles of the above 10 metastasis-related DEGs in colorectal cancer patients. Higher expression of CLSTN2 was markedly correlated with worse OS and metastasis-free survival (MFS) (p < 0.05; Figures 8A,B). In contrast, higher expression of REG3A was...
Risk Score and Survival Analysis

Next, we compared the performance of identified individual genes with the combined gene signature panel. First, we used step multivariate Cox regression analysis to establish a gene signature with prognostic value for COAD. According to the results, the risk scoring system for each patient was calculated as follows: risk score = \( \text{LEP} \times 0.134582 + \text{REG3A} \times (–0.05402) + \text{DLX2} \times 0.211469 \), after which the patients were classified into a low-risk (\( n = 178 \)) or a high-risk (\( n = 178 \)) group based on the median risk score. As shown in Supplementary Figure 1A, patients in high-risk group had significantly poorer survival compared with those in low-risk group (log-rank test, \( p < 0.05 \)). Subsequently, to evaluate the prognostic value of risk score, we drew the ROC curve at 5 years of OS and calculated the AUC value. From Supplementary Figure 1B, the 5 year AUC was 0.672 (AUC > 0.65), which revealed superior predictive accuracy in OS (19).
FIGURE 4 | (A) Venn diagram depicting the overlap between the targets of the DEMiRNAs and DEGs. (B) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of 14 DEMiRNAs based on the DIANA database. (C) Enriched ontology clusters of the 127 genes overlapping the targets of the DEMiRNAs and DEGs based on the Metascape database. (D) The top 30 genes evaluated by connectivity degree in the PPI network of the 127 genes. The color from red to yellow represents the connectivity degree from high to low.

FIGURE 5 | The regulatory network between DEMiRNAs and hub genes. (A) Upregulated miRNAs. (B) Downregulated miRNAs.
FIGURE 6 | Kaplan-Meier analysis of LEP (A) and DLX2 (B) in the TCGA-COAD cohort. Kaplan-Meier analysis of LEP (C) and DLX2 (D) in the M0 stage TCGA-COAD cohort. Kaplan-Meier analysis of LEP (E) and DLX2 (F) in the M1 stage TCGA-COAD cohort.
Second, for the individual genes, the correlations between their expression levels and prognosis are shown in Figure 6. Similarly, the ROC curves at 5 years of OS were plotted based on the risk score of each sample. Additionally, the 5 year AUC of LEP, DLX2, CLSTN2, and REG3A were 0.638, 0.622, 0.5, and 0.62, respectively (AUC < 0.65), indicating that the combined gene signature panel have better performance on evaluating the prognosis of COAD patients.

Functional Enrichment and Related Diseases of the Four Prognosis-Related Genes

Figures 6–8 show that the key genes, including LEP, DLX2, CLSTN2, and REG3A, are associated with the prognosis of COAD patients. To learn more about the four genes, we analyzed their GO term enrichment related to biological processes, molecular functions, and cellular components (Supplementary Table 3). Notably, both LEP and REG3A were involved in the regulation of the extracellular space. DLX2 participated in modulating DNA binding-related processes, transcription, and cell differentiation. CLSTN2 played a role in homophilic cell adhesion via plasma membrane adhesion molecules. Subsequently, the CTD was used to investigate the diseases related to these genes, and the results showed that all four genes are relevant to colonic neoplasms (Supplementary Table 4).

The Four Prognosis-Related Genes Expressions Are Correlated With Immune Infiltration Level and Immune Markers in COAD

As tumor microenvironment, especially immune cells play an important role in metastasis (20, 21), we explored whether the four genes expressions are correlated with immune cells and immune-related markers in COAD.

As for immune cells, LEP expression level had significantly positive correlations with infiltrating levels of CD4+ T cells ($r = 0.244, p = 7.65e-07$), macrophages ($r = 0.434, p = 6.07e-20$), neutrophils ($r = 0.332, p = 8.77e-12$), and dendritic cells (DCs) ($r = 0.361, p = 8.73e-14$) (Figure 9A). In addition, there were weak
correlations between DLX2 expression level and infiltrating levels of B cells, CD4+ T cells, and DCs (Figure 9B). Furthermore, there were significantly positive correlations between CLSTN2 expression level and infiltrating levels of CD4+ T cells ($r = 0.44$, $p = 2.00e-20$), macrophages ($r = 0.405$, $p = 2.33e-17$), and DCs ($r = 0.266$, $p = 6.01e-08$) (Figure 9C). On the other hand, REG3A expression level had weak negative correlations with infiltrating levels of CD4+ T cells and macrophages in COAD (Figure 9D).

As regard to metastasis-related immune markers (Table 3). After the correlation adjustment by purity, the results revealed that the LEP expression level was significantly positively correlated with 18 immune markers among 22 metastasis-related markers. DLX2 and CLSTN2 expression levels were significantly positively correlated with 11 and 16 immune markers, respectively. However, among 22 metastasis-related immune markers, REG3A expression level was significantly positively correlated with two immune markers and significantly negatively correlated with three markers in COAD.

Expression of Four Prognosis-Related Genes in Colorectal Cancer
To better understand the potential of these prognosis-related genes as drug targets, we analyzed their expression levels in normal tissues and colorectal cancer tissues using ONCOMINE 4.5 database. The results revealed that mRNA expression levels of these four genes were significantly higher in colorectal cancer tissues than in normal tissues ($p < 0.01$). Although the fold differences of LEP, DLX2, and CLSTN2 were within 2, they ranked within the top 20% based on mRNA expression (Over-expression Gene Rank (LEP): in top 20%; Over-expression Gene Rank (DLX2): in top 11%; Over-expression Gene Rank (CLSTN2): in top 14%; (Supplementary Figures 2A–C)). In addition, REG3A expression level was significantly higher in colorectal cancer tissues than in normal colon tissues (Supplementary Figure 2D).

Prediction of Potential Therapeutic Drugs for COAD
Given the strong association between distant metastasis and the survival of cancer patients, we postulated that drugs affecting the DEGs in metastatic patients may play an antitumor role in cancer treatment. Among the 127 candidate DEGs, 49 upregulated and 27 downregulated genes were selected as input files for the CMap pilot dataset. As a result, four compounds (Mean $\leq -0.40$, $p < 0.05$, percent non-null $> 50$) were considered candidate drugs: ajmaline, a class IA antiarrhythmic drug used diagnostically (not...
FIGURE 9 | Correlations of the four prognosis-related genes with various immune cells in COAD (TIMER). The correlation between the abundance of immune cell and the expression of (A) LEP, (B) DLX2, (C) CLSTN2, and (D) REG3A. The x axis indicates the prognosis related genes and y axis indicates immune cell types. Each dot represents a sample, and the blue line represents the relationship between the expression level of each gene and immune cell contents.

used therapeutically) to elicit ECG changes in patients suspected to have Brugada syndrome; TTNPB, a synthetic retinoid that acts as a selective agonist for retinoic acid receptors (RARs); dydrogesterone, a progestogen drug used to treat menstrual and premenstrual disorders, endometriosis, infertility and other conditions; and dicycloverine, also known as dicyclomine, an anticholinergic drug used for treating irritable bowel syndrome (IBS) (Table 4). Then, the relationships between the four compounds and cancers were investigated using CTD, and the results revealed that ajmaline, TTNPB, and dydrogesterone could target colonic neoplasms (Supplementary Table 5).

DISCUSSION

In this study, we identified four novel distant metastasis-related genes significantly associated with the survival of COAD patients. In brief, we screened 127 DEGs by comparing the gene expression profiles of primary tumors from metastatic patients with those from primary patients. Most previous studies focused on the differentially expressed regulators between tumor tissue and normal tissue (22–24). However, in the present study, we analyzed DEmiRNAs and DEGs between non-distinct metastatic and distant metastatic COAD patients. The overlap between distant metastasis-related genes and prognostic factors represents an important group of potential biomarkers and therapeutic targets. Moreover, the expression levels of LEP, DLX2, CLSTN2, and REG3A were significantly higher in tumor tissues than normal tissues. Based on this, we determined four small-molecule drugs (ajmaline, TTNPB, dydrogesterone, and dicycloverine) that potentially target these genes according to the data from CMap. As the CMap results are based on small-molecule perturbations profiled across a large number of cell types (17), we further validated the relationships between the four candidate drugs and colon carcinoma in CTD. Among the four drugs, the results suggested that three drugs, including ajmaline, TTNPB, and dydrogesterone, could treat colon carcinoma.

Notably, compared to four individual prognosis-associated genes, the combined gene signature panel had better discrimination performance in COAD patients. LEP was reported to promote cancer cell migration and invasion (25, 26). DLX2 was indicated to increase the risk of metastasis in prostate cancer patients with a high expression of Ki67 (27). In addition, CLSTN2 was demonstrated to be involved in both the tumorigenesis and pulmonary metastasis of osteosarcoma (28).
TABLE 3 | Correlation analysis between four identified genes and immune-related markers in COAD (TIMER).

| Gene markers | LEP | DLX2 | CLSTN2 | REG3A |
|--------------|-----|------|--------|-------|
|              | None | Purity | None | Purity | None | Purity | None | Purity |
|              | Cor  | p     | Cor  | p     | Cor  | p     | Cor  | p     |
| CCL2         | 0.455*** | 0.438*** | 0.167 | 0.154 | 0.036 | 0.469 | 0.378*** | 0.360*** |
| TGFβ (TGFB1) | 0.369*** | 0.314*** | 0.377 | 0.167*** | 0.148 | 0.167*** | 0.377 | 0.379*** |
| CTLA4        | 0.249*** | 0.219*** | 0.529 | 0.021 | 0.667 | 0.029 | 0.542 | 0.071*** |
| CCL5         | 0.266*** | 0.249*** | 0.013 | 0.112 | 0.201 | 0.199*** | 0.201 | 0.360*** |
| IL10         | 0.381*** | 0.370*** | 0.377 | 0.169*** | 0.076 | 0.106 | 0.076 | 0.044*** |
| COX2 (PTGS2) | 0.289**  | 0.133**  | 0.222 | 0.075 | 0.039 | 0.532 | 0.201 | 0.055*** |
| VEGF (VEGFA) | 0.162   | 0.154   | 0.510*** | 0.098 | 0.069 | 0.164 | 0.027 | 0.565   |
| PD-1 (PDCD1) | 0.217*** | 0.187*** | 0.118 | 0.112 | 0.098 | 0.112 | 0.012 | 0.101   |
| PD-L1 (CD274) | −0.060 | 0.599 | 0.243*** | 0.016 | 0.112 | 0.376*** | 0.384*** | 0.374*** |
| CXCL5        | 0.142   | 0.096   | 0.052 | 0.068 | 0.069 | 0.165 | 0.057 | 0.222   |
| CXCL8 (IL8)  | 0.207*** | 0.180*** | 0.050 | 0.283 | 0.032 | 0.520 | 0.068 | 0.146   |
| CSF1         | 0.417*** | 0.401*** | 0.106 | 0.100 | 0.376 | 0.383*** | 0.384 | 0.374*** |
| MMP9         | 0.149   | 0.189   | 0.156 | 0.187 | 0.065 | 0.162 | 0.057 | 0.252   |
| COX14 (THBD) | 0.397*** | 0.367*** | 0.119 | 0.106 | 0.510 | 0.530*** | 0.510 | 0.358   |
| CCL22        | 0.062   | 0.586   | 0.182 | 0.082 | 0.079 | 0.112 | 0.311 | 0.311*** |
| CD11c (ITGAX) | 0.469*** | 0.432*** | 0.110 | 0.106 | 0.322 | 0.326*** | 0.322 | 0.326*** |
| CXCL12       | 0.424*** | 0.425*** | 0.084 | 0.074 | 0.072 | 0.145 | 0.491 | 0.504*** |
| CCL17        | 0.200*** | 0.146**  | 0.031 | 0.502 | 0.005 | 0.915 | 0.270 | 0.262*** |
| VISTA (C10orf54) | −0.002 | 0.986 | 0.252*** | 0.023 | 0.617 | 0.004 | 0.944 | 0.262 | 0.236*** |
| CD25 (IL2RA) | 0.293*** | 0.263*** | 0.129** | 0.119 | 0.232 | 0.215*** | 0.232 | 0.215*** |
| HGF          | 0.350*** | 0.337*** | 0.018 | 0.694 | 0.003 | 0.948 | 0.589 | 0.596*** |
| FOXP3        | 0.131*** | 0.249*** | 0.094 | 0.428 | 0.103 | 0.096 | 0.052 | 0.359*** |

COAD, colon adenocarcinoma; Cor, R value of Spearman’s correlation; None, correlation without adjustment. Purity, correlation adjusted by purity. *p < 0.05; **p < 0.01; ***p < 0.001.
Interestingly, REG3A was found to promote cell proliferation in gastric and colorectal cancers (29, 30). However, the present study found that REG3A correlates with favorable survival in colorectal cancer, and is down-regulated in primary tumors of patients with distant metastasis (M1) compared to patients without distant metastasis (M0). Consistent with this result, Qiu et al. reported that REG3A was a tumor suppressor in gastric cancer, while REG3A overexpression could inhibit the invasion and proliferation and promote the apoptosis of gastric cancer cells via the phosphatidylinositol 3-kinase (PI3K)/Akt-GSK3 signaling pathway axis (31). From this perspective, REG3A might promote tumor cells proliferation, but suppress metastatic cascade indirectly. The understanding of the roles of these four genes in the metastasis of colorectal cancer may be improved by analyzing larger cohorts and performing in vitro and in vivo experiments.

In general, tumor development could be controlled by cytotoxic innate and adaptive immune cells. However, cancer cells evolve different mechanisms that mimic peripheral immune tolerance to avoid tumoricidal attack. Furthermore, increasing evidence reveals that tumor-infiltrating immune cells could promote the metastatic cascade thus affecting clinical outcome (32, 33). In this study, we found that expression of LEP, DLX2, CLSTN2, and REG3A are correlated with immune infiltrating levels of CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and DCs in COAD, indicating that these four prognosis-associated genes expression levels could also reflect immune status, which partially explains that LEP, DLX2 and CLSTN2 are predictors of poor outcome while REG3A indicates better outcome and lower probability of distant metastasis in COAD.

To develop more treatment options for COAD, we found that three existing drugs may be used for treating COAD. First, ajmaline, an indole alkaloid commonly used for hypertension, was found to inhibit DNA synthesis by arresting cells at the G2 phase and promoting apoptosis in prostate cancer cells (34). As a voltage-gated Na+ channels (VGSCs) blocker, ajmaline preferentially binds to the open state of cardiac Na+ channel protein (Nav1.5) (35). In recent years, VGSCs have been recognized as the invasiveness-associated proteins, and they are exclusively highly expressed in aggressive tumor biopsies and metastatic cancer cells (36–38). Specifically, Nav1.5, a neonatal splice variant of VGSCs, has been found to promote the breast cancer cell invasion in vitro and metastasis in vivo (39). Thus, VGSCs are a class of promising anti-metastasis drug targets (40), especially Nav1.5, which is a neonatal isoform not commonly expressed in normal adult tissues (41, 42). There are numerous clinically used drugs that target Nav1.5, but some undesirable effects such as local anesthetics, antiarrhythmics, and anticonvulsants restrict their application in treating metastatic cancers (43). More recently, researchers are focusing on exploring the proper dose of old drugs and developing novel tissue-specific drugs to treat metastatic cancers by inhibiting VGSCs. For example, Shilpa et al. designed and synthesized five small molecule compounds to inhibit the invasion of MDA-MB-231 cells (a highly aggressive human breast cancer cell line) through blocking Nav1.5-dependent inward currents (44). Moreover, Hatice et al. reported that low concentrations of naringenin (5 and 10 µM), a natural compound found in citrus fruits and tomatoes, could inhibit MAT-LyLu cells (a highly metastatic prostate cancer cell line) metastasis by blocking VGSCs (45). Also, Nelson et al. proposed that phenytoin, a sodium channel-blocking antiepileptic drug, at a dose equivalent to that used to treat epilepsy (60 mg/kg; daily), could significantly reduce breast tumor metastasis to the liver, lungs, and spleen in orthotopic tumor models (46). Besides, Baptista-Hon et al. showed that VGSCs expressed in colon cancer cells could promote invasion. Apart from this, ropivacaine, an inhibitor of Nav1.5, could inhibit invasion of SW620 cells (a metastatic colon cancer cell line), with a dose of inhibition of 3.8 µM (47). Second, TTNPB is a retinoic acid analog that acts as a selective RAR agonist. It has been reported that an analog of TTNPB, 4-hydroxybenzyl-modified compound (4HBTTNPB), could induce apoptosis in breast cancer cells (48). For dydrogesterone, only one case has been reported. In brief, one patient with recurrent endometrial stromal sarcoma was treated exclusively with dydrogesterone at a daily dose of 10 mg, and the tumor clinically disappeared after 4 years and 3 months (49). To date, no studies have focused on the three drugs in COAD. Therefore, future studies are needed to explore the key molecular targets and therapeutic effects of these three drugs in COAD.

In summary, we identified four novel prognosis-related genes and three potential drugs for COAD patients, which may serve to unravel the complex gene networks of distant metastasis with clinical relevance.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the article/Supplementary Material.
AUTHOR CONTRIBUTIONS

MW participated in its design, analysis, interpretation, and manuscript drafting. WL assisted in making the study design and evaluating the results obtained. X-FY supervised the study, participated in its design, interpretation, analysis, and including drafting. All authors contributed to drafting, reviewing the manuscript, and approved the submission of the final version.

FUNDING

This work was supported in part by funding from the Chinese Ministry of Science and Technology (No. 2018ZX10731101-001-014) and National Natural Science Foundation of China (Nos. 31970151, 81772169, 32041006, and 81802351).

ACKNOWLEDGMENTS

We thank the associate editor and the reviewers for their helpful remarks. We are also grateful to Dr. Juan Zhang for her excellent assistance in data analysis. We would like to thank Springer Nature Author Services (authorservices.springernature.com) for English language editing.

REFERENCES

1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. (2017) 67:177–93. doi:10.3322/caac.21395
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. (2019) 69:7–34. doi:10.3322/caac.21551
3. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. (2017) 394:1467–80. doi:10.1016/S0140-6736(19)32319-9
4. Rong Z, Rong Y, Li Y, Zhang L, Zou B, et al. Development of a novel six-miRNA-based model to predict overall survival among colon adenocarcinoma patients. Front Oncol. (2020) 10:26. doi:10.3389/fonc.2020.00026
5. Peng H, Zhang Y, Zhou Z, Guo Y, Huang X, Westover KD, et al. Intergraded analysis of ELM01, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma. ElBioMedicine. (2019) 46:105–18. doi:10.1016/j.ebiom.2019.07.002
6. Mody K, Bekaii-Saab T. Clinical trials and progress in metastatic colon cancer. Surg Oncol Clin N Am. (2018) 27:349–65. doi:10.1016/j.soc.2017.11.008
7. Mejri N, Dridi M, El Benna H, Labidi S, Daoud N, Roussen H. Tumor location impact in stage II and III colon cancer: epidemiological and outcome evaluation. J Gastrointest Oncol. (2018) 9:263–8. doi:10.21037/jgo.2017.12.02
8. Tokar T, Pastrello C, Rossos AEM, Abovsky M, Hauschild AC, Tsay M, et al. mirDIP 4.1-integrative database of human microRNA target predictions. Nucleic Acids Res. (2018) 46:D360–70. doi:10.1093/nar/gkt1144
9. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. (2011) 39:D561–8. doi:10.1093/nar/gkq1973
10. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. (2003) 13:2498–504. doi:10.1101/gr.1239303

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.576615/full#supplementary-material

Supplementary Figure 1 | Prognostic value of the combined gene signature panel. (A) K-M curve based on low-risk group and high-risk group. (B) ROC curve (AUC = 0.672). K-M, Kaplan-Meier; OS, overall survival; ROC, operating characteristic curve; AUC, area under the curve.

Supplementary Figure 2 | Expression of four selected genes in colorectal cancer (Oncomine database). Box plots derived from mRNA expression data in Oncomine are shown, comparing expression of specific genes in normal and tumor tissues. "p < 0.05, **p < 0.01, and ***p < 0.001. (A) Comparison of LEP mRNA expression (Skrzypczak Colorectal 2). (B) Comparison of DLX2 mRNA expression (TCGA Colorectal). (C) Comparison of CLSTN2 mRNA expression (Graudens Colon). (D) Comparison of REG3A mRNA expression (TCGA Colorectal).

Supplementary Table 1 | Identification of differentially expressed genes (DEGs) in TCGA-COAD patients with or without distant metastasis.

Supplementary Table 2 | Shared genes between the targets of the DEMRNAs and DEGs.

Supplementary Table 3 | Gene Ontology (GO) term enrichment for the prognosis-associated genes differentially expressed in distant metastatic COAD.

Supplementary Table 4 | The relationship between cancers and prognosis-associated genes differentially expressed in distant metastatic COAD based on CTD.

Supplementary Table 5 | Relationship between cancers and three potential drugs for COAD based on CTD.

11. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. (2019) 47:W556–60. doi:10.1093/nar/gkz430
12. Goswami CP, Nakshatri H. PROGeneV2: enhancements on the existing database. BMC Cancer. (2014) 14:970. doi:10.1186/1471-2407-14-970
13. Vlachos IS, Zagganas K, Paraskevopoulos MD, Georganakos G, Karagkouni D, Vergoulis T, et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. (2015) 43:W460–6. doi:10.1093/nar/gkq403
14. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. (2019) 10:1523. doi:10.1038/s41467-019-09234-6
15. Munoz-Torres M, Carbon S. Get GO! retrieving GO data using AmiGO, QuickGO, API, files, and tools. Methods Mol Biol. (2017) 1446:149–60. doi:10.1007/978-1-4939-3743-1_11
16. Davis AP, Grondin CJ, Johnson RJ, Scicky D, King BL, McMorrin R, et al. The comparative toxicogenomics database: update 2017. Nucleic Acids Res. (2017) 45:D972–8. doi:10.1093/nar/gkw838
17. Subramanian A, Narayan R, Corsoello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: Li000 platform and the first 1,000,000 profiles. Cell. (2017) 171:1437–52 e17. doi:10.1016/j.cell.2017.10.049
18. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. (2017) 77:108–10. doi:10.1158/0008-5472.CAN-17-0307
19. Jia M, Yao L, Yang Q, Chi T. Association of MSH2 expression with tumor mutational burden and the immune microenvironment in lung adenocarcinoma. Front Oncol. (2020) 10:168. doi:10.3389/fonc.2020.00168
20. Azimi F, Scolyer RA, Rumcheva P, NONciemf M, Murzai R, McCarthy SW, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. (2012) 30:2678–83. doi:10.1200/JCO.2011.37.8339
21. Smith HA, Kang Y. The metastasis-promoting roles of tumor-associated immune cells. J Mol Med. (2013) 91:411–29. doi:10.1007/s00109-013-1021-5
22. Yang H, Lin HC, Liu H, Gan D, Jin W, Cui C, et al. A 6 IncRNA-based risk score system for predicting the recurrence of colon adenocarcinoma patients. *Front. Oncol.* (2020) 10:81. doi: 10.3389/fonc.2020.00081

23. Liu Y, Liu B, Jin G, Zhang J, Wang X, Feng Y, et al. An integrated three-long non-coding RNA signature predicts prognosis in colorectal cancer patients. *Front. Oncol.* (2019) 9:1269. doi: 10.3389/fonc.2019.01269

24. Ahluwalia P, Mondal AK, Bloomer C, Fulzele S, Jones K, Ananth S, et al. Identification and clinical validation of a novel 4 gene-signature with prognostic utility in colorectal cancer. *Int J Mol Sci.* (2019) 20:3818. doi: 10.3390/ijms20153818

25. Juarez-Cruz JC, Zuniga-Eulogio MD, Olea-Flores M, Castaneda-Saucedo E, Mendoza-Catalan MA, Ortuno-Pineda C, et al. Leptin induces cell migration and invasion in a FAK-Src-dependent manner in breast cancer cells. *Endocr Connect.* (2019) 8:1539–52. doi: 10.1530/EC-19-0442

26. Ghasemi A, Saedi J, Azimi-Nejad M, Hashemy SI. Leptin-induced signaling pathways in cancer cell migration and invasion. *Cell Oncol.* (2019) 42:243–60. doi: 10.1007/s13402-019-00428-0

27. Green WJ, Ball G, Hulman G, Johnson C, Van Schalwyk G, Ratan HL, et al. KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approach. *Br J Cancer.* (2016) 115:236–42. doi: 10.1038/bjc.2016.169

28. Xie L, Yao Z, Zhang Y, Li D, Hu F, Liao Y, et al. Deep RNA sequencing reveals the dynamic regulation of miRNA, IncRNAs, and mRNAs in osteosarcoma tumorigenesis and pulmonary metastasis. *Cell Death Dis.* (2018) 9:772. doi: 10.1038/s41419-018-0813-5

29. Chen ZF, Huang ZM, Xue HB, Lin XQ, Chen RP, Chen MJ, et al. REG3A promotes the proliferation, migration, and invasion of gastric cancer cells. *Onco Targets Ther.* (2017) 10:2017–23. doi: 10.2147/OTT.S131443

30. Ye Y, Xiao L, Wang SJ, Yue W, Yin QS, Sun MY, et al. Up-regulation of REG3A in colorectal cancer cells confers proliferation and correlates with colorectal cancer risk. *Onco-target.* (2016) 7:3921–33. doi: 10.18632/oncotarget.6473

31. Qiu YS, Liao GJ, Jiang NN. REG3A overexpression suppresses gastric cancer cell invasion, proliferation and promotes apoptosis through P3K/Akt signaling pathway. *Int J Mol Med.* (2018) 41:3167–74. doi: 10.3892/ijmm.2018.3520

32. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. *Genes Dev.* (2018) 32:1267–84. doi: 10.1101/gad.314617.118

33. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. *Nat Rev Immunol.* (2015) 15:73–86. doi: 10.1038/nri3789

34. Ramamurthy MD, Kumar A, Ayavu M, Dhriaviam KN. Reserpine induces apoptosis and cell cycle arrest in hormone independent prostate cancer cells through mitochondrial membrane potential failure. *Anticancer Agents Med Chem.* (2018) 18:1313–22. doi: 10.2174/1871520618666180209152215

35. Lei M, Wu L, Terrar DA, Huang CL. Modernized classification of cardiac antiarrhythmic drugs. *Circulation.* (2018) 138:1879–96. doi: 10.1161/CIRCULATIONAHA.118.035455

36. Brackenbury WJ. Voltage-gated sodium channels and metastatic disease. *Channels.* (2012) 6:352–61. doi: 10.4161/chann.21910

37. House CD, Vaske CJ, Schwartz AM, Obias V, Frank B, Luu T, et al. Voltage-gated Na+ channel SCN5A is a regulator of a gene transcriptional network that controls colon cancer invasion. *Cancer Res.* (2010) 70:6957–67. doi: 10.1158/0008-5472.CAN-10-1169

38. Roger S, Gillet L, Le Guennec JY, Besson P. Voltage-gated sodium channels and cancer: is excitability their primary role? *Front Pharmacol.* (2015) 6:152. doi: 10.3389/fphar.2015.00152

39. Brisson L, Gillet L, Calaghan S, Besson P, Le Guennec JY, Roger S, et al. Na(V)1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H(+) efflux in caveolae. *Oncogene.* (2011) 30:2070–6. doi: 10.1038/onc.2010.574

40. Chahine M, Desaphy JF. Editorial: recent advances in voltage-gated sodium channels, their pharmacology and related diseases. *Front Pharmacol.* (2016) 7:20. doi: 10.3389/fphar.2016.00020

41. Driftov V, Gillet L, Bon E, Marionneau-Lambot S, Oullier T, Jolin V, et al. Nanolize inhibits NaV1.5-mediated breast cancer cell invasiveness and lung colonization. *Mol Cancer.* (2014) 13:264. doi: 10.1186/1476-4598-13-264

42. Yang M, Kozminski DJ, Wold LA, Modak C, Calhoun JD, Isom LL, et al. Therapeutic potential for phenytoin: targeting Na(V)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer. *Breast Cancer Res Treat.* (2012) 134:603–15. doi: 10.1007/s10549-012-2102-9

43. Fozzard HA, Sheets MF, Hanck DA. The sodium channel as a target for local anesthetic drugs. *Front Pharmacol.* (2011) 2:68. doi: 10.3389/fphar.2011.00068

44. Dutta S, Lopez Charcas O, Tanner S, Gradek F, Driftov V, Roger S, et al. Discovery and evaluation of nNav1.5 sodium channel blockers with potent cell invasion inhibitory activity in breast cancer cells. *Biorg Med Chem.* (2018) 26:2428–36. doi: 10.1016/j.biopha.2018.07.008

45. Nelson M, Yang M, Dowle AA, Thomas JR, Brackenbury WJ, The sodium channel-blocking anti-epileptic drug phenytoin inhibits breast tumour growth and metastasis. *Mol Cancer.* (2015) 14:13. doi: 10.1186/s12943-014-0277-x

46. Baptista-Hon DT, Robertson FM, Robertson GB, Owen SJ, Rogers GW, Lydon EL, et al. Potent inhibition by ropivacaine of metastatic colon cancer SW620 cell invasion and NaV1.5 channel function. *Br J Anaesth.* (2014) 113:Suppl. 1:139–48. doi: 10.1093/bja/aeu104

47. Anding AL, Nieves NJ, Abzanidze VV, Collins MD, Curley RW Jr, Clagett-Dame M. 4-Hydroxybenzyl modification of the highly teratogenic retinoid, 4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-1-propen-1-yl]benzoic acid (TTNPB), yields a compound that induces apoptosis in breast cancer cells and shows reduced teratogenicity. *Chem Res Toxicol.* (2011) 24:1853–61. doi: 10.1021/tx200174n

48. Akashi D, Todo Y, Shimada C, Okamoto K, Minobe S, Kato H. Successful use of dydrogesterone as maintenance therapy in recurrent endometrial stromal sarcoma: a case report. *Jpn J Clin Oncol.* (2013) 43:1145–9. doi: 10.1093/jjco/hyt142

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Wu, Lou, Lou, Fu and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction which does not comply with these terms.